Charité - Universitätsmedizin Berlin

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time (2022) Rejeski K, Perez AP, Iacoboni G, Buecklein VL, Blumenberg V, Völkl S, Penack O, et al. Conference contribution ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (2022) Ernst T, Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, et al. Conference contribution S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid (2022) Hofmann SC, Gunther C, Bockle BC, Didona D, Ehrchen J, Gaskins M, Geerling G, et al. Journal article ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, et al. Journal article, Editorial LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT (2022) Weller J, Zeyen T, Schlegel U, Lazaridis L, Werner JM, Onken J, Zeiner P, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Standardized High-Quality Processes for End-of-Life-Decision Making in the Intensive Care Unit Remain Robust during an Unprecedented New Pandemic—A Single-Center Experience (2022) Marsch F, Spies CD, Francis R, Graw JA Journal article Erratum: Antihistone Properties of C1 Esterase Inhibitor Protect against Lung Injury (2022) Wygrecka M, Wujak L, Markart P, Kosanovic D, Müller-Redetzky HC, Witzenrath M, Henneke I, et al. Journal article, Erratum Seizure Semiology in Antibody-Associated Autoimmune Encephalitis (2022) Kaaden T, Madlener M, Angstwurm K, Bien CG, Bogarin Y, Doppler K, Finke A, et al. Journal article